The HDHD2 Knockout NCI-H1975 Polyclonal Cells comprise a heterogeneous population of CRISPR/Cas9-edited human lung adenocarcinoma epithelial cells engineered to disrupt the HDHD2 gene. This polyclonal knockout product serves as a versatile loss-of-function model for investigating pseudouridine-5′-phosphatase activity and its roles in nucleotide metabolism, RNA modification, and cancer cell biology. The targeted gene disruption enables systematic dissection of HDHD2-dependent pathways in a clinically relevant non-small cell lung cancer background.
NCI-H1975 is a widely utilized cell line derived from the pleural effusion of a non-smoking female patient with non-small cell lung adenocarcinoma. These cells exhibit an epithelial morphology and retain key characteristics of metastatic lung cancer, including robust proliferation and invasive potential, making them a clinically relevant host for oncogenic and metabolic studies. Their established background in cancer research provides a convenient pivot to examine how HDHD2 modulates malignancy-associated metabolic rewiring.
HDHD2 encodes a pseudouridine-5′-phosphatase that catalyzes the dephosphorylation of pseudouridine monophosphate to pseudouridine, a critical step linking RNA turnover to pyrimidine salvage. Functioning downstream of cellular nucleotide sensors and nutrient-sensing pathways, HDHD2 activity modulates the intracellular pool of pseudouridine, which can be further converted to uracil by pseudouridine kinase and pyrimidine nucleoside phosphorylases. The enzyme is thus integrated into a network where pseudouridine-5′-phosphate, pseudouridine, and the salvage enzyme machinery coordinate to influence nucleotide homeostasis and RNA modification dynamics. Although direct interacting partners remain poorly defined, HDHD2 is predicted to associate with other nucleotide salvage factors, and its disruption is expected to perturb the balance between RNA catabolism-derived pseudouridine and reutilization pathways.
In the NCI-H1975 lung adenocarcinoma background, disruption of HDHD2 provides a powerful tool to dissect the metabolic dependencies of cancer cells. Lung tumors frequently reprogram nucleotide metabolism to sustain proliferation, and pseudouridine salvage may represent an underappreciated vulnerability. This knockout model enables direct interrogation of how impaired pseudouridine recycling influences nucleotide pool balance, RNA modification patterns, and phenotypes such as proliferation, invasion, and drug sensitivity in a metastatic epithelial context.
Researchers can utilize these polyclonal knockout cells for a range of experimental applications, including the study of pyrimidine salvage and catabolism, metabolic reprogramming in lung adenocarcinoma, and the role of RNA modification dynamics in tumor progression. Standard validation methods such as western blotting and RT-qPCR confirm HDHD2 disruption, while functional assays??including LC-MS-based pseudouridine quantification, nucleotide pool profiling, and RNA modification analysis??allow for detailed phenotypic characterization. This model is also suited for cell proliferation studies and drug screening campaigns aimed at identifying modulators of nucleotide metabolism. For further information or to discuss custom applications, please contact Ascent Research.
